Corcept Therapeutics Inc (NASDAQ: CORT). Meaningful positive changes in fundamentals have recently occurred: the consensus estimate for December, 2025 increased significantly, the consensus estimate for December, 2024 increased significantly, and significant quarterly earnings acceleration occurred.
Recent notable positive changes in investment behavior have benefitted Corcept Therapeutics Inc (NASDAQ: CORT): the stock’s recent price rise disrupted its longer term downtrend.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
CORT is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Corcept Therapeutics has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Corcept Therapeutics has a poor Appreciation Score of 21 but a good Power Rating of 85, and the Neutral Value Trend Rating results.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock increased 1.5% on 9/11/24. The shares closed at $35.55. However, unusually low trading volume at 60% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 3.8% during the last week.
Be the first to comment